Építés alatt – nem éles oldal
Belépés
Befejeződött4. fázis

Xofluza-Wearables Feasibility-Study

A legfontosabb adatok

Ki végzi
Children's Hospital of Philadelphia
Hol
Philadelphia (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
4. fázis
Résztvevők
498 fő vett részt
Kezdés
2023. dec. 14.
Befejezés
2025. ápr. 30.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
A vizsgált kezelések
  • Baloxavir Marboxil
A regiszteradat frissítve
2025. július 11.

Ki vehet részt

Életkor
2 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 31 feltétel megnézéseKevesebb

Ki vehet részt

  • Population 1: Potential Baloxavir treatment group (CHOP transplant subjects 5 years \& up)
  • Willing CHOP male or female kidney, heart, liver or lung single or multiple transplant recipients aged 5 years or older as per FDA guidelines
  • Willing to regularly wear a smartwatch and take an at-home positive respiratory virus (RV) panel which will include a diagnoses of Influenza A or B
  • Have an antigen positive diagnoses of Influenza A or B (a PCR-based positive clinical diagnoses of Influenza A or B may be requested in "alarm positive plus antigen positive but asymptomatic" cases)
  • Can be included if their treating physician prescribe prophylactic treatment of Baloxavir if the subject has been exposed to Influenza
  • If Baloxavir is prescribed the study subject should be treated within 48 hours of symptom onset (regardless of the alarming time); Population 2: Potential Baloxavir treatment group (CHOP waitlisted subjects 5 years \& up)
  • Willing waitlisted CHOP kidney, heart, liver or lung single or multiple transplant recipients aged 5 years or older, which are anticipated to have a transplant in the next 12 months; Population 3: Potential Baloxavir treatment group (non-transplanted household members)
  • Non-transplanted household member of a CHOP transplant recipient or waitlisted patient
  • Be at least 5 years of age
  • Willing to regularly wear a smartwatch and take an at-home positive respiratory virus (RV) panel for diagnoses of Influenza A or B
  • Have a Antigen-based positive diagnoses of Influenza A or B; Population 4: Non-Baloxavir treatment subjects
  • CHOP transplant recipients and all other non-transplanted household members who are 2-4 years of age
  • Subjects 5 years and up who are Influenza positive but whom do not receive Baloxavir treatment

Ki nem vehet részt

  • Any allergy to Baloxavir (although they can remain in the study as an influenza case or control without Baloxavir treatment, or if they have been treated with a different medication for influenza) or a recommendation from the study physicians'/transplant pharmacist(s) not to take Baloxavir
  • If the subject is taking a prohibited medication. These include Influenza antiviral drugs with the exception of oseltamivir and baloxavir (such as peramivir, laninamivir, zanamivir, rimantadine, umifenovir or amantadine)
  • A household transplant recipient is not participating in the study
  • A recommendation from the study physicians'/transplant pharmacist not to take Baloxavir
  • If the subject is taking a prohibited medication. These include Influenza antiviral drugs with the exception of oseltamivir and baloxavir (such as peramivir, laninamivir, zanamivir, rimantadine, umifenovir or amantadine)
  • If the subject is pregnant or breast feeding at the time of early infection alerting
  • Any allergy to Baloxavir (although they will remain in the study as an influenza case/control without treatment)
  • If the subject is younger than 5 years of age
  • If the subject is younger than 5 years of age
  • Population 1:
  • Subjects weighing < 20 kg
  • If the subject is unable or unwilling to consent
  • If the subject requires mechanical ventilation at time of enrollment
  • Unwilling or unable to comply with the study requirements; Population 2: All exclusion criteria listed for Population 1; Population 3:
  • Subjects weighing < 20 kg
  • If the subject is unable or unwilling to consent
  • If the subject is pregnant at screening
  • Unwilling or unable to comply with the study requirements

Helyszínek itt: Egyesült Államok

  • Children's Hospital of PhiladelphiaPhiladelphia, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this prospective, interventional, single-center study is to assess whether the early detection of Influenza with smart wearable device algorithms and alerting, rapid testing, and subsequent Baloxavir treatment demonstrate better post-infection outcomes versus publicly available- and Centers for Disease Control (CDC)-derived national statistics for equivalent household populations as well as pediatric kidney, heart, liver, lung transplant recipients and waitlisted patients.

A vizsgálat 4 csoportja

  • Population 1: Transplant RecipientsA vizsgált kezelés

    Participants who are a CHOP kidney, heart, liver or lung single or multiple transplant recipients aged 5 years or older will receive a single dose of Baloxavir.

    Kezelés: Baloxavir Marboxil

  • Population 2: Waitlisted Patients for TransplantA vizsgált kezelés

    Participants who are waitlisted CHOP kidney, heart, liver or lung single or multiple transplant recipients aged 5 years or older will receive a single dose of Baloxavir marboxil.

    Kezelés: Baloxavir Marboxil

  • Population 3: Household Members (Non-Transplant)A vizsgált kezelés

    Non-Transplanted Household Members aged 5 years or older will receive a single dose of Baloxavir marboxil.

    Kezelés: Baloxavir Marboxil

  • Population 4: Non-Baloxavir treatment subjectsNincs vizsgálati kezelés, összehasonlításként

    CHOP transplant recipients and all other non-transplanted household members who are 2-4 years of age. Subjects 5 years and up who are Influenza positive but whom do not receive Baloxavir treatment

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Feasibility Study of Xofluza Treatment of Influenza in Pediatric Transplant Recipients, Waitlisted Subjects and Household Members After Early Infection Alerting Using Wearable Devices
A regiszteradat frissítve
2025. július 11.